Medtronic (NYSE:MDT) Releases FY25 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $5.44-5.50 for the period, compared to the consensus EPS estimate of $5.45. Medtronic also updated its FY 2025 guidance to 5.440-5.500 EPS.

Wall Street Analyst Weigh In

MDT has been the subject of a number of analyst reports. Daiwa America raised shares of Medtronic to a “strong-buy” rating in a research note on Friday, August 23rd. Robert W. Baird increased their price target on Medtronic from $90.00 to $96.00 in a research note on Friday. Oppenheimer boosted their price objective on Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. Royal Bank of Canada upgraded Medtronic from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $98.00 to $105.00 in a research report on Thursday, October 10th. Finally, Piper Sandler upped their price target on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Hold” and a consensus price target of $95.80.

Medtronic Stock Performance

NYSE:MDT opened at $87.64 on Tuesday. The firm has a market capitalization of $112.39 billion, a PE ratio of 29.61, a PEG ratio of 2.50 and a beta of 0.84. The stock’s fifty day moving average is $89.42 and its 200 day moving average is $84.82. Medtronic has a fifty-two week low of $74.66 and a fifty-two week high of $92.68. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.01. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The firm had revenue of $8.40 billion during the quarter, compared to analysts’ expectations of $8.27 billion. During the same period in the previous year, the company earned $1.25 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Medtronic will post 5.44 earnings per share for the current year.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.